版本:
中国

BRIEF-Eleven Biotherapeutics reports Q4 loss per share $0.15

March 24 Eleven Biotherapeutics Inc:

* Eleven Biotherapeutics reports fourth quarter and full year 2016 financial results

* Q4 loss per share $0.15

* Q4 revenue $800,000 versus $600,000

* Eleven Biotherapeutics Inc- cash and cash equivalents were $25.3 million as of December 31, 2016, compared to $36.1 million as of December 31, 2015

* Eleven Biotherapeutics Inc- Eleven expects to have cash to fund research and development programs and operations into early 2018.

* Eleven Biotherapeutics - topline phase 3 data for lead drug candidate vicinium, in development for non-muscle invasive bladder cancer, expected in 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐